＜臨床脂質学，第２版＞
Clinical Lipidology, 2nd ed.
- A Companion to Braunwald's Heart Disease
| 著者 | : C.M.Ballantyne |
|---|---|
| 出版社 | : ELSEVIER |
| ISBN | : 978-0-323-28786-9 |
| ページ数 | : 550pp.(379illus.) |
| 出版年 | : 2015年 |
在庫
定価40,535円(本体36,850円 ＋ 税)
※在庫表示「なし」の商品は海外発注にて注文を承ります。概ね4〜6週間で取寄可能です（「近刊」の商品は刊行後の入荷・発送になります）。
なお、海外発注後のキャンセルはお受けできかねますのでご了承ください。
- 商品説明
- 主要目次
心臓病学の金字塔 "Braunwald’s Heart Disease" を部分的に補完・敷衍するコンパニオン・タイトルの一つ，臨床脂質学の改訂第2版． 基礎科学からアテローム血栓症の病因論，危機診断，治療法の選択まで，高コレステロール患者の治療の先端情報を供覧している． 斯界の権威による確固たる内容を，アルゴリズムを使いながら分かりやすく説いている． ExpertConsultが付属し，全文検索や画像のダウンロードが容易にできる．
Section 1 Basic Mechanisms
1. Human Plasma Lipoprotien Metabolism
2. Regulation and Clearance of Apolipoprotein B-Containing Lipoproteins
3. Absorption and Excretion of Intestinal Cholesterol and Other Sterols
4. High-Density Lipoprotein Metabolism
5. Lipoproteins: Mechanisms for Atherogenesis and Progression of Atherothrombotic Disease
6. Impact of Rare and Common Genetic Variants on Lipoprotein Metabolism
7. Lipoprotein Oxidation: Mechanisms and Biotheranostic Applications
Section 2 Risk Assessment
8. Cholesterol: Concentration, Ratio, and Particle Number
9. High-Density Lipoprotein Cholesterol and Triglycerides in Coronary Heart Disease Risk Assessment
10. Lipoprotein(a)
11. Clinical Evaluation for Genetic and Secondary Causes of Dyslipidemia
12. Use of High Sensitivity C-Reactive Protein for Risk Assessment
13. Role of Lipoprotein-Associated Phospholipase A2 in Vascular Disease
14. Emerging Assays
15. Imaging Atherosclerosis for Risk Stratification by Cardiac Computed Tomography or Carotid Ultrasound
Section 3 Therapy
16. Overview of General Approach to Management of Elevated Low-Density Lipoprotein Cholesterol and Mixed Dyslipidemia, High Triglycerides, and Low High-Density Lipoprotein Cholesterol
17. Treatment Guidelines Overview
18. Dietary Patterns for the Prevention and Treatment of Cardiovascular Disease
19. Exercise and Lipids
20. Weight Loss
21. Statins
22. Bile Acid Sequestrants
23. Cholesterol Absorption Inhibitors
24. Niacin (Nicotinic Acid)
25. Fibrates
26. Omega-3 Fatty Acids
27. Combination Therapy for Dyslipidemia
28. Nutriceuticals and Functional Foods for Cholesterol Reduction
29. Evolving Targets of Therapy: Cholesteryl Ester Transfer Protein Inhibition
30. Evolving Targets of Therapy: Proprotein Convertase Subtilisin/Kexin 9 Inhibition
31. Evolving Targets of Therapy: Inflammation as a Method to Predict and Prevent Cardiovascular Events
32. Invasive Imaging Modalities and Atherosclerosis: Intravascular Ultrasound
33. Noninvasive Imaging Modalities and Atherosclerosis: The Role of Ultrasound
34. Noninvasive Imaging Modalities and Atherosclerosis: The Role of Magnetic Resonance Imaging and Positron Emission Tomography Imaging
35. Special Patient Populations: Diabetes and Metabolic Syndrome
36. Special Patient Populations: Women and Elderly
37. Special Patient Populations: Children and Adolescents
38. Special Patient Populations: Familial Hypercholesterolemia and other Severe Hypercholesterolemias
39. Special Patient Populations: Acute Coronary Syndromes
40. Special Patient Populations: Transplant Recipients
41. Special Patient Populations: Chronic Kidney Disease
42. Special Patient Populations: Lipid Abnormalities in High-Risk Ethnic Groups
43. Special Patient Populations: Human Immunodeficiency Patients
44. Therapeutic Targeting of High-Density Lipoprotein Metabolism
